Sight Sciences, Inc. (NASDAQ:SGHT) Receives Average Recommendation of "Hold" from Analysts

Shares of Sight Sciences, Inc. (NASDAQ:SGHT - Get Free Report) have earned an average rating of "Hold" from the seven ratings firms that are covering the firm, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and two have issued a buy recommendation on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $3.83.

A number of research analysts have weighed in on the company. Piper Sandler decreased their price objective on Sight Sciences from $5.50 to $3.50 and set a "neutral" rating on the stock in a report on Thursday, March 6th. UBS Group decreased their price target on shares of Sight Sciences from $5.50 to $5.00 and set a "buy" rating on the stock in a research note on Monday, January 27th. Lake Street Capital dropped their price objective on shares of Sight Sciences from $3.00 to $2.50 and set a "hold" rating for the company in a research note on Thursday, March 6th. Citigroup decreased their target price on shares of Sight Sciences from $4.60 to $3.00 and set a "neutral" rating on the stock in a research note on Tuesday, March 4th. Finally, Needham & Company LLC restated a "hold" rating on shares of Sight Sciences in a report on Wednesday, April 9th.

Insider Buying and Selling at Sight Sciences

In related news, CEO Paul Badawi sold 24,174 shares of Sight Sciences stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $2.30, for a total value of $55,600.20. Following the completion of the transaction, the chief executive officer now owns 6,010,580 shares in the company, valued at approximately $13,824,334. The trade was a 0.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Manohar K. Raheja bought 10,000 shares of Sight Sciences stock in a transaction on Wednesday, March 12th. The shares were acquired at an average price of $2.73 per share, for a total transaction of $27,300.00. Following the completion of the acquisition, the executive vice president now owns 145,000 shares in the company, valued at $395,850. This represents a 7.41 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 35,196 shares of company stock valued at $81,001 over the last 90 days. 28.90% of the stock is owned by insiders.

Institutional Trading of Sight Sciences

Hedge funds have recently modified their holdings of the stock. WealthTrust Asset Management LLC increased its holdings in Sight Sciences by 230.2% during the 1st quarter. WealthTrust Asset Management LLC now owns 43,590 shares of the company's stock worth $105,000 after purchasing an additional 30,390 shares during the period. Foster Victor Wealth Advisors LLC purchased a new stake in shares of Sight Sciences during the first quarter worth approximately $85,000. B. Riley Wealth Advisors Inc. raised its holdings in Sight Sciences by 24.6% in the fourth quarter. B. Riley Wealth Advisors Inc. now owns 243,082 shares of the company's stock valued at $885,000 after acquiring an additional 48,000 shares in the last quarter. Squarepoint Ops LLC lifted its stake in Sight Sciences by 314.2% in the fourth quarter. Squarepoint Ops LLC now owns 169,211 shares of the company's stock worth $616,000 after acquiring an additional 128,355 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in Sight Sciences during the 4th quarter worth approximately $36,000. 55.51% of the stock is currently owned by institutional investors and hedge funds.

Sight Sciences Trading Down 1.0 %

Shares of NASDAQ:SGHT opened at $3.05 on Monday. The business's 50 day moving average price is $2.65 and its 200-day moving average price is $3.31. Sight Sciences has a 1 year low of $2.03 and a 1 year high of $8.45. The firm has a market capitalization of $157.67 million, a price-to-earnings ratio of -2.99 and a beta of 2.46. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74.

Sight Sciences (NASDAQ:SGHT - Get Free Report) last released its earnings results on Wednesday, March 5th. The company reported ($0.23) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.01). The company had revenue of $19.07 million for the quarter, compared to analysts' expectations of $18.98 million. Sight Sciences had a negative return on equity of 47.28% and a negative net margin of 63.30%. During the same period in the prior year, the firm earned ($0.22) EPS. On average, equities research analysts forecast that Sight Sciences will post -0.99 earnings per share for the current fiscal year.

Sight Sciences Company Profile

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.